How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Hiv Rapid Test Market
- By Product Type: Oral Fluid-Based Rapid Tests, Blood-Based Rapid Tests, Fingerstick Blood Rapid Tests, Serum/Plasma-Based Rapid Tests
- By End User: Hospitals, Diagnostic Laboratories, Clinics and Physician Offices, Community Testing Centers, Home Testing
- By Technology: Immunochromatographic Assays, Enzyme-Linked Immunosorbent Assay (ELISA) Rapid Tests, Lateral Flow Assays, Nucleic Acid Amplification Tests (NAAT) Rapid Formats
- By Test Format: Single-Test Kits, Multiplex Test Kits, Self-Test Kits
- By Application: HIV Screening, Confirmatory Testing, Early Detection and Diagnosis, Monitoring and Follow-up
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Oral Fluid-Based Rapid Tests leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the Hiv Rapid Test Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 4
End User 5
Technology 4
Test Format 3
Application 4
Companies profiled
Abbott Laboratories
OraSure Technologies Inc.
bioMérieux SA
F. Hoffmann-La Roche AG
Alere Inc. (now part of Abbott)
Siemens Healthineers
Becton
Dickinson and Company (BD)
Chembio Diagnostics Inc.
Trinity Biotech plc
LumiraDx Ltd
SD Biosensor Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →OraSure Technologies Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →bioMérieux SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →F. Hoffmann-La Roche AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Alere Inc. (now part of Abbott)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Chembio Diagnostics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Trinity Biotech plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →LumiraDx Ltd
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →SD Biosensor Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Mylan N.V. (now part of Viatris)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →MedMira Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sekisui Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Wondfo Biotech Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,865M by 2033 · 11.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Oral Fluid-Based Rapid Tests56.6
- Blood-Based Rapid Tests14.7
- Fingerstick Blood Rapid Tests13.4
- Serum/Plasma-Based Rapid Tests15.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$841.8M → $1,801M · 10.0%
Europe$586.7M → $1,393M · 11.4%
Asia Pacific$535.7M → $1,288M · 11.6%
Latin America$331.6M → $786.2M · 11.4%
Middle East and Africa$255.1M → $603.4M · 11.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.912026
10.932027
10.942028
10.952029
10.972030
10.992031
11.002032
11.002033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories18.0
- OraSure Technologies Inc.16.3
- bioMérieux SA8.9
- F. Hoffmann-La Roche AG12.1
- Alere Inc. (now part of Abbott)7.7
- Siemens Healthineers9.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type20.6%
End User23.5%
Technology14.7%
Test Format23.8%
Application17.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.7
- Europe23.7
- Asia Pacific21.9
- Latin America13.4
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 74 | 98 | 84 | 98 | 78 | 76 | 85 |
| OraSure Technologies Inc. | 91 | 71 | 89 | 70 | 78 | 79 | 80 |
| bioMérieux SA | 81 | 81 | 80 | 62 | 87 | 77 | 78 |
| F. Hoffmann-La Roche AG | 74 | 64 | 72 | 75 | 79 | 68 | 72 |
| Alere Inc. (now part of Abbott) | 71 | 75 | 55 | 69 | 76 | 70 | 69 |
| Siemens Healthineers | 52 | 57 | 71 | 59 | 60 | 58 | 60 |
| Becton | 46 | 53 | 53 | 59 | 42 | 51 | 51 |
| Dickinson and Company (BD) | 46 | 46 | 40 | 36 | 50 | 50 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- OraSure Technologies Inc.
- bioMérieux SA
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| OraSure Technologies Inc. | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| bioMérieux SA | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| F. Hoffmann-La Roche AG | ◐ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Alere Inc. (now part of Abbott) | ✓ | ◐ | ◐ | ◐ | ✓ | − |
| Siemens Healthineers | − | − | ◐ | ◐ | ◐ | − |
| Becton | ◐ | − | − | − | − | ◐ |
| Dickinson and Company (BD) | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories85
2OraSure Technologies Inc.80
3bioMérieux SA78
4F. Hoffmann-La Roche AG72
5Alere Inc. (now part of Abbott)69
6Siemens Healthineers60
7Becton51
8Dickinson and Company (BD)45
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Abbott LaboratoriesOraSure Technologies Inc.bioMérieux SA
Challenger2
Strong scale, closing on the leaders.
F. Hoffmann-La Roche AGAlere Inc. (now part of Abbott)
Contender1
Focused players with pockets of strength.
Siemens Healthineers
Niche2
Specialists in a single segment or region.
BectonDickinson and Company (BD)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Hiv Rapid Test Market — a $75M beachhead inside a $1.10B market.
Beachhead (SOM)$75Mobtainable near-term
Serviceable (SAM)$410Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Oral Fluid-Based Rapid Tests
Best fit — highest urgency & budget in Product Type.
Economic buyer77 fit
Blood-Based Rapid Tests
Strong fit — clear ROI and a fast path to value.
End user67 fit
Fingerstick Blood Rapid Tests
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Hiv Rapid Test Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified23%
Evaluation12%
Closed-won5%
$16.1KCAC
$70KLTV
4.4:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Hiv Rapid Test Market is a durable-growth opportunity — $5.80B by 2033, compounding at 9.2%.
TAM · 2025$2.86Btoday
TAM · 2033$5.80Bforecast
CAGR9.2%2027–2033
Cumulative$37.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.80BTotal addressable market
SAM$2.29BServiceable available market
SOM$488MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.2% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.80BLarge & growingTAM by 2033 at 9.2% CAGR
$2.29BServiceable nowreachable with today’s model
$488MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.53BBear6.0% CAGR
$5.80BBase9.2% CAGR
$7.43BBull12.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Hiv Rapid Test Market — a $1.34B market by 2033. Plan: grow share from 7.1% to 14.1%.
Market size · 2033$1.34Btotal addressable
Market CAGR10.2%2027–2033
Target share14.1%from 7.1% today
Revenue ambition$188Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.1% | 14.1% | Behind |
| Revenue | $104M | $188M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.1% | 40.3% | On track |
| Customer retention | 87.2% | 93.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $28M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Hiv Rapid Test Market conversation — a $3.11B market you can size, segment and defend in minutes.
Market size · 2033$3.11Btotal opportunity
Growth8.4%CAGR to 2033
Addressable buyers1,356+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 4 mopayback period
$60K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Abbott LaboratoriesOraSure Technologies Inc.bioMérieux SAF. Hoffmann-La Roche AGAlere Inc. (now part of Abbott)Siemens HealthineersBectonDickinson and Company (BD)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Hiv Rapid Test Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Hiv Rapid Test Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Hiv Treatment Drug Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportHiv Vaccine Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportHiv-Aids Testing Instruments Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportHIV-associated Nephropathy Treatment Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportHJT Cell Market
Market size, share, segmentation and regional forecast.
$552M market · 2025 base year
View reportHMC and HBM Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportHMDS (CAS No. 999-97-3) Market
Market size, share, segmentation and regional forecast.
$794M market · 2025 base year
View reportH-MET-OIPR HCL CAS 85391-05-5 Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportHMGB1 ELISA Kit Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportHmg-Coa Reductase Inhibitor Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportHMI Panel PC Market
HMI Panel PC Market is valued at USD 1.38 Billion in 2025 and is expected to reach USD 2.1 Bill…
$1.4B market · 2025 base year
View reportHMP Multifunctional Leather Chemical Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.